2026年2月8日，创立于2013年的柳州知名美食品牌"掌小鸭"在马来西亚槟城海外首店启动试业。这标志着凭借卤 味闻名柳州的品牌正式迈出国际化布局的关键一步，将柳州地道风味引入东南亚市场。 掌小鸭品牌由李金蕾女士于2013年创立，自诞生之日起便秉持对美食的极致追求与诚信经营理念。品牌早期推出 的泡椒鸭掌、泡椒鸭翅等新派卤味迅速风靡柳州市场，并于同年10月在柳州市中心五星街开设首间直营店。通过 与消费者零距离接触积累了深厚的口味数据库与口碑沉淀。截至2017年，掌小鸭实体店规模已发展至30余家，覆 盖柳州多个区域。 为确保槟城店地道风味，掌小鸭特派柳州研发团队赋能，驻店数周对本地员工开展全流程技艺培训：从香料配 比、火候掌控到卤汁养护，手把手传授柳州老卤精髓。所有产品均在店内现制现售，既保留柳州风味灵魂，又结 合东南亚饮食偏好微调辣度与香型，实现"技术输出、本地制作、文化融合"的经营理念。 掌小鸭马来西亚槟城店的试业，标志着品牌正式迈向国际化。未来，掌小鸭计划继续推进"文化+创新"战略，通过 数字化商城与本地化运营，让广西的地方风味飘香世界。 ...

Group 1 - The company has completed a restructuring of its board of directors and specialized committees, with Lian Jian appointed as the chairman and executive director, marking a significant change in leadership [1][3] - The new board members possess strong backgrounds in finance, capital, and law, which aligns well with the company's future development strategy [3] - The restructuring is seen as a crucial step for the company to optimize governance, integrate resources, and enhance competitiveness, signaling a new phase of high-quality development [3] Group 2 - The strategic direction of the company has become clearer with the change in major shareholders and the establishment of the new board, focusing on the core business of cloud communication and embracing AI and internationalization [5]

Core Viewpoint - The report from CICC indicates that Green Tea Group (06831) is the leading company in the domestic casual Chinese dining sector, specifically in Jiangsu and Zhejiang cuisine, with projected EPS of 0.74/0.91/1.1 yuan for 2025-2027 and a CAGR of 22% from 2025 to 2027, corresponding to a P/E of 7 times for 2026, with a target price of 10 HKD, representing a 47% upside potential [1] Group 1: Business Growth Drivers - The company is expected to enhance its performance through increased takeout revenue and store expansion, with takeout revenue currently below the industry average but anticipated to grow as the company invests more in this area [2] - As of June 30, 2025, the proportion of stores in second-tier, third-tier, and lower cities is projected to rise from 21%/20% in 2022 to 25%/26%, indicating a positive outlook for the company's penetration in lower-tier cities [2] - The company has opened 5 restaurants in Hong Kong and plans to open 10 and 13 new restaurants in Hong Kong, Southeast Asia, and North America in 2026 and 2027, respectively, marking steady progress in international expansion [2] Group 2: Product Development and Store Optimization - The company is focusing on innovative dish development to attract diverse consumer groups, leveraging its strong R&D capabilities in fusion cuisine, which is expected to enhance brand image and customer experience [3] - The optimization of the single-store model has led to a reduction in store size from 450 square meters to 300 square meters, resulting in lower rental and personnel costs, thereby facilitating accelerated national expansion [3] Group 3: Market Differentiation - The company aims to address market concerns regarding "fashion risk" by optimizing its single-store model to lower investment costs and improve same-store performance, with expectations of an increase from 23% in 1H25 to 28% in 2026 [4] - The company is considered to have attractive valuation metrics, positioning it favorably within the market [4]

春回大地，万象启新！2026年2月4日，恰逢立春时节。在国家1类新药琥珀八氢氨吖啶片获批进入倒计时的关键节点，为深化推进集团创新转型，加速集 团北京总部暨北京科创中心的战略落地，大兴区委书记初军威、区长刘洋、副区长安学军等区领导隆重会见金马药业集团董事长张玉富先生一行。 区委书记初军威介绍大兴区产业布局，区长刘洋，副区长安学军陪同参观 双方以春为约，围绕创新药获批后的总部建设、科创中心落地、新药生产及商业化推广、神经领域创新药持续投入和研发、智能医疗生态构建等核心议题 深度磋商，达成全方位共识，为金马药业扎根"中国药谷"、赋能首都医药健康产业高质量发展注入磅礴动能，让合作共赢的信心与春天的朝气一同升腾！ 集团医疗板块总裁、建设板块总裁，研发副总裁、金融副总裁、IT总监陪同调研。 参观北京市大兴区营商服务中心 行程伊始，在区委书记初军威、区长刘洋、副区长安学军等区领导的全程陪同下，集团项目工作组走进大兴区营商服务中心。 初军威书记亲自推介区域发展优势：大兴区立足首都都市圈核心枢纽定位，坐拥临空经济区、自贸区、综保区"三区叠加"的独特政策红利，联动京津冀协 同发展的战略价值凸显。全区锚定生命健康、临空产业、先进制 ...

21世纪经济报道记者唐唯珂 1月29日，三友医疗披露的业绩预告显示，2025年公司营业收入预计达5.35亿-5.62亿元，同比增长17.95%-23.90%；归母净利润更是实现5600 万-7280万元，较2024年的1146.86万元暴增388.29%-534.78%，扣非后归母净利润成功扭亏为盈。 2026年初，骨科赛道上市公司2025年度业绩预告密集披露，行业呈现"头部强者恒强、创新企业负重前行"的鲜明分化格局。 "无源+有源"疗法协同成为核心增长引擎，子公司水木天蓬的超声骨刀、超声吸引设备等产品营收与净利润快速增长，同时控股公司Implanet 的国际化业务表现亮眼，2025年营收1247.39万欧元，同比增长32.62%，其中美国市场增速高达49.30%，成为业绩重要增量。 春立医疗、三友医疗等龙头企业净利润实现数倍增长，奥精医疗成功扭亏为盈，核心受益于集采"以价换量"释放与国际化突破；而聚焦高端创 新赛道的天智航虽营收增速超50%，却仍未摆脱亏损困境。 春立医疗的业绩爆发力更为突出。2月3日披露的预告显示，2025年归母净利润预计为2.45亿-2.88亿元，同比增幅96.01%-130.41%；扣 ...

格隆汇2月3日｜长江证券研报指出，中国中免收购DFS大中华区业务，港股定增引进LVMH，国际化布 局更进一步。展望后市，中国中免是我国免税行业领军企业，经过40年的发展，已经积累了渠道、规 模、精细化运营管理、品牌等多维度的核心竞争优势。盈利预测及投资建议：看好公司，奋力创新，行 稳致远，未来，在拓宽海内外市场、丰富产品品类、提升消费者体验、优化门店运营等方面持续发力， 实现收入业绩稳健增长。预计2025-2027年归母净利润分别为36.86/42.67/49.66亿元，对应PE分别为 50.16/43.33/37.23X，维持"买入"评级。 ...

Group 1 - The energy storage industry has shown strong market vitality at the beginning of 2026, with significant developments including a strategic partnership between CATL, Schroders Greencoat, and Lochpine Capital to develop energy storage projects in Europe, targeting a total capacity of 10GWh [2][3][5] - The collaboration aims to create a complete closed loop of "technology + capital + projects," with CATL providing battery technology support, Schroders leveraging its asset management expertise in renewable energy, and Lochpine focusing on project development and fund operations [3][5] - CATL's order capacity for energy storage projects is projected to exceed 300GWh in 2025, making it the leading company in terms of annual order capacity in the energy storage sector [5] Group 2 - Far East Holdings announced it has won contracts totaling approximately 5.94 billion RMB for energy storage systems, with a year-on-year increase of 115.57% in contract orders exceeding 10 million RMB [6][7] - The contracts involve projects in both China and Europe, with specific amounts of 5.8 billion RMB and 14.32 million RMB for different contracts [6][7] - Far East Holdings expects to achieve profitability in 2025, with a projected net profit of 45 million to 65 million RMB, attributed to improvements in its "smart battery" business segment [7]

Core Insights - In January 2026, the company delivered a total of 20,011 new vehicles, which is expected to reduce carbon emissions by approximately 300,000 tons over their lifecycle compared to traditional fuel vehicles, equivalent to the carbon absorption of 4.94 million medium-sized trees over 10 years [1][4] Group 1: Vehicle Deliveries and Sales Performance - The Xiaopeng X9 model continued to perform strongly, with 4,219 units delivered in January, representing a year-on-year increase of 413.9% [1][4] - As of the end of January, the cumulative delivery of the Xiaopeng X9 reached 51,897 units, making it the fastest model among domestic new energy MPVs to surpass the 50,000 mark [1][4] Group 2: New Product Launches - The 2026 version of the Xiaopeng X9 pure electric model has begun pre-orders, marketed as the "longest-range 5C pure electric large seven-seater" [1][4] Group 3: Technological Advancements - The company is set to launch its self-developed second-generation VLA, which is the industry's first physical world model to achieve L4 initial capabilities, in the first quarter [1][4] Group 4: International Expansion - By the end of 2025, the company plans to enter 60 countries and regions globally, with over 380 overseas stores and a charging network covering 31 countries and regions, connecting to over 2.66 million charging piles [1][4] - The company has established nine major R&D centers worldwide to further enhance its international brand presence [1][4]

Core Viewpoint - Changchun High-tech expects a significant decline in net profit for 2025, projecting between 150 million to 220 million yuan, attributed to increased R&D and sales expenses, as well as strategic adjustments in product delivery to mitigate potential impairment losses [1][2]. Group 1: Financial Performance - The company anticipates a net profit drop for 2025 compared to the previous year, with a forecast of 150 million to 220 million yuan [1]. - Increased R&D expenses and sales costs are impacting short-term profitability, as the company invests in new product development and market promotion [2][3]. - Adjustments in product sales policies and pricing, in response to industry changes and market conditions, have also contributed to reduced revenue and net profit [2]. Group 2: R&D and Product Development - Changchun High-tech is focusing on traditional strengths in endocrine metabolism and women's health, while also exploring innovative directions in oncology, respiratory, and immune-related fields [2]. - The company is actively increasing R&D investments, with several new products entering clinical stages, which is expected to yield long-term benefits despite short-term financial pressures [3]. - The company aims to enhance its R&D efficiency and develop sustainable long-term capabilities by exploring multi-line layouts and systemic solutions in various health sectors [3]. Group 3: Strategic Initiatives - Changchun High-tech is pursuing international expansion and has established a partnership with ALK for specific immunotherapy products, marking a significant step in the Chinese desensitization treatment market [3]. - The company is also planning to list in Hong Kong to strengthen its global strategy and enhance its financing capabilities, aiming to attract international investment for its clinical trials and R&D [4]. - The focus on building an innovative cooperation platform is part of the company's strategy to advance its international presence and drive growth [4].

铭科精技机构调研报告 调研日期: 2026-01-30 铭科精技控股股份有限公司是一家专业从事汽车精密冲压模具和汽车零部件冲压、焊接及组装的企业,其集团拥有先进的模具制造技术和精密冲压技术 ,为客户提供精密冲压模具和汽车零部件的一体化解决方案。集团在国内拥有十多家制造基地,全面覆盖国内六大汽车产业集群。自设立以来,铭科精技一 直将自主研发和技术创新作为发展的持续动力,现已被认定为"国家高新技术企业"、"东莞市市级倍增企业"、"东莞市上市企业",并被中国模具工 业协会评为"中国汽车零部件冲压模具重点骨干企业"、"2017-2020年度模具出口重点企业"等。铭科精技的汽车零部件业务逐步彰显规模,并获得 了多家全球知名汽车零部件一级供应商的认可,服务于宝马、奔驰、奥迪、日产、本田、丰田、通用、小鹏汽车、赛力斯等品牌汽车,为其提供精密汽车 冲压模具及汽车零部件。铭科精技的业务范围分布在美国、西班牙、法国、德国、捷克、英国、墨西哥、日本等国家。 | 2026-01-30 | 副董事长、总经理 杨国强,独立董事 郁京凯,副总经理、董事会秘书 蔡玲莉 ,华林证券保荐代表人 李露,证券事务 代表 张尧 | | --- | - ...